Curated by THEOUTPOST
On Fri, 28 Feb, 4:07 PM UTC
2 Sources
[1]
Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - Spectral AI (NASDAQ:MDAIW), Spectral AI (NASDAQ:MDAI)
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI MDAI ("Spectral AI" or the "Company"), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: 844-481-3008 - U.S.412-317-1892 - International A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company's website at https://investors.spectral-ai.com/news-events/events About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by "Seeing the Unknown®" with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com. Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements. For Media and Investor Relations, please contact: David Kugelman Atlanta Capital Partners LLC (866) 692-6847 Toll Free - U.S. & Canada (404) 281-8556 Mobile and WhatsApp Email: dk@atlcp.com MDAISpectral AI Inc$1.72-0.58%OverviewMDAIWSpectral AI Inc$0.476510.8%Market News and Data brought to you by Benzinga APIs
[2]
Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call
DALLAS, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) ("Spectral AI" or the "Company"), developer of the AI-driven DeepView System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration ("FDA") in 2018 and uses multi-spectral imaging and AI algorithms to predict burn healing potential, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 27, 2025 after the close of the stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time to discuss the results. Investors interested in participating in the live call can dial: A simultaneous webcast of the call may be accessed online from the Events & Presentations section of the Investor Relations page of the Company's website at https://investors.spectral-ai.com/news-events/events About Spectral AI Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by "Seeing the Unknown" with its DeepView System. DeepView is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com. Forward Looking Statements Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward- looking statements. Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward- looking statements.
Share
Share
Copy Link
Spectral AI, developer of the AI-driven DeepView® System for burn healing prediction, schedules its Q4 and full year 2024 financial results conference call for March 27, 2025.
Spectral AI (NASDAQ: MDAI), a Dallas-based predictive AI company specializing in medical diagnostics, has announced that it will release its financial results for the fourth quarter and full year of 2024 on Wednesday, March 27, 2025, after the stock market closes 12. The company will follow this with a conference call at 5:00 pm Eastern Time to discuss the results with investors and analysts.
Spectral AI is at the forefront of revolutionizing wound care management with its AI-driven DeepView® System. This innovative technology, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential 12.
The DeepView® System is designed to provide clinicians with an objective and immediate assessment of a wound's healing potential before treatment or medical intervention. This predictive diagnostic tool aims to significantly improve the current standard of care by offering faster and more accurate treatment insights, potentially leading to better patient outcomes and reduced healthcare costs 12.
Investors interested in participating in the live call can dial:
Additionally, a simultaneous webcast of the call will be accessible online from the Events & Presentations section of the Investor Relations page on Spectral AI's website 12.
As with many companies in the medical technology sector, Spectral AI has included forward-looking statements in its announcement. These statements, protected under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, relate to the company's strategy, plans, objectives, and financial outlook 12.
However, investors are cautioned that these forward-looking statements are not guarantees of future performance. The company acknowledges that there are known and unknown risks, uncertainties, and other important factors that could cause actual results to differ materially from those projected in the forward-looking statements 12.
Spectral AI's work with the DeepView® System represents a significant application of artificial intelligence in healthcare, particularly in wound care and burn treatment. The company's focus on using AI for faster and more accurate treatment decisions could potentially set new standards in medical diagnostics and patient care strategies 12.
As Spectral AI prepares to share its financial results, the medical and tech communities will be watching closely to gauge the progress and potential of AI-driven diagnostic tools in clinical settings. The upcoming financial report and conference call may provide valuable insights into the commercial viability and future prospects of AI applications in healthcare.
Spectral AI, an AI company focused on medical diagnostics in wound care, has scheduled its 2024 third quarter financial results and conference call for November 6, 2024.
2 Sources
2 Sources
Spectral AI, a medical technology company, adds three new clinical trial sites for its DeepView® system and increases its patent portfolio to 26 granted patents, bolstering its position in AI-driven medical imaging.
4 Sources
4 Sources
Spectral AI has installed three DeepView System devices in Australian hospitals, marking a significant step in the global deployment of its AI-powered burn wound assessment technology.
2 Sources
2 Sources
Spectral AI, a medical technology company, expands its burn study with new clinical trial sites and achieves significant patient enrollment milestones in its U.S. Burn Pivotal Study.
2 Sources
2 Sources
Spectral AI completes proof-of-concept for a module in its DeepView® System, offering precise burn wound measurement and healing potential assessment using AI technology.
2 Sources
2 Sources
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
© 2025 TheOutpost.AI All rights reserved